Claims for Patent: 4,760,071

Summary for Patent: 4,760,071

Title:	17.beta.-N-monosubstituted carbamoyl-4-aza-5.alpha.-androst-1-en-3-ones which are active as testosterone 5.alpha.-reductase inhibitors
Abstract:	This invention is for the compound 17.beta.-(N-t-butylcarbamoyl)-4-aza-5.alpha.-androst-1-en-3-one, pharmaceutical compositions containing the compound, methods of inhibiting testosterone 5.alpha.-reductase with the compound and methods of treating hyperandrogenic conditions with the compound, particularly benign prostatic hypertrophy.
Inventor(s):	Rasmusson; Gary H. (Watchung, NJ), Reynolds; Glenn F. (Westfield, NJ)
Assignee:	Merck & Co., Inc. (Rahway, NJ)
Application Number:	06/800,623
Patent Claims:	1. 17.beta.(N-t-butylcarbamoyl)-4-aza-5.alpha.-androst-1-en-3-one. 2. A method of treating the hyperandrogenic condition of acne vulgaris, seborrhea, femal hirsutism, and benign prostatic hypertrophy comprising administration to a patient in need of such treatment of a therapeutically effective amount of the compound of claim 1. 3. A method of inhibiting testosterone 5.alpha.-reductase in a patient in need of such inhibiting treatment, comprising administration to such a patient of a therapeutically effective amount of the compound of claim 1. 4. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and an effective amount of the compound claim 1.